120
Participants
Start Date
April 9, 2021
Primary Completion Date
September 8, 2021
Study Completion Date
August 9, 2022
rVSVΔG-ZEBOV-GP, V920
The experimental vaccine is the rVSVΔG-ZEBOV-GP, an Ebola vaccine.
Fibre and equilibrate breakfast and lunch
Participants receive fibres and caloric equilibrate diet during breakfast and lunch every day for 21 consecutive days.
Active detection and treatment of pathogens
Monthly diagnostic and treatment of childhood infections Active detection and treatment of pathogens.
Fibre and equilibrate breakfast and lunch plus Active detection and treatment of pathogens
Participants receive fibres and caloric equilibrate diet during breakfast and lunch every day for 21 consecutive days and diagnostic and treatment of childhood infections Active detection and treatment of pathogens every month for 12 months
Chikenpox or Varicella vaccine (VARILRIX)
The active comparator vaccine, a Varicella vaccine (VARILRIX®)
Placebo
About 30 children do not receive diet, nor active pathogen detection
Centre de Recherches Médicales de Lambaréné, Lambaréné
Merck Sharp & Dohme LLC
INDUSTRY
Centre de Recherche Médicale de Lambaréné
OTHER